Diabetes
Diabetes is a growing disease and an enormous global burden that is projected to affect more than 592 million people by 2035. AstraZeneca is pushing the boundaries of science with the goal of developing life-changing medicines that aim to reduce the global burden and complications of diabetes.
Our commitment to diabetes is exemplified by the depth and breadth of our global clinical research program. AstraZeneca is committed to advancing understanding of the treatment effects of our diabetes medicines in broad patient populations, as well as exploring combination treatment approaches to help more patients achieve treatment success earlier in their disease progression. Our ambition is to reduce the long-term impact of diabetes.
Type 2 diabetes is a metabolic disorder characterised by chronically high levels of glucose in the blood. Find out more about the condition and its prevalence.
-
Bydureon (exenatide) 2mg prolonged-release suspension for injection in a pre-filled pen (BCise) is indicated in adult patients, 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including basal insulin, when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control.
-
Please note, the Bydureon Dual Chamber Pen is being replaced by the Bydureon BCise 2 mg prolonged-release suspension for injection in pre-filled pen as of 31st December 2020. For questions relating to the supply of this product, please contact the AstraZeneca Supply Chain Team on 0800 0320501 or visit the Supply Chain website: https://medicines.astrazeneca.co.uk/home/supply-of-astrazeneca-medicines/supply-of-medicines.html
-
Forxiga (dapagliflozin) is indicated in adults for the treatment of insufficiently controlled type 2 diabetes
-
Xigduo (dapagliflozin/metformin hydrochloride) is indicated in adults for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
-
Onglyza (saxagliptin) is indicated in adults with type 2 diabetes mellitus to improve glycaemic control in combination with diet and exercise.
-
QTERN (saxagliptin/ dapagliflozin), fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus.
- Bydureon BCise (exenatide) – Great Britain Prescribing information
- Bydureon BCise (exenatide) – Northern Ireland Prescribing information
- Forxiga (dapagliflozin) Type 2 diabetes mellitus - Great Britain Prescribing Information
- Forxiga (dapagliflozin) Type 2 diabetes mellitus - Northern Ireland Prescribing Information
- Xigduo (dapagliflozin and metformin HCI) Prescribing Information
- ONGLYZA (saxagliptin) Prescribing Information
- QTERN (saxagliptin/ dapagliflozin) - Great Britain Prescribing Information
- QTERN (saxagliptin/ dapagliflozin) - Northern Ireland Prescribing Information
GB-37921 July 2022